2238 Sato, Takemi - Thomas Jefferson University - Thomas Jefferson University

Takemi Sato, MD

Contact Dr. Sato

111 South 11th Street
Suite 4240
Philadelphia, PA 19107

(215) 955-8874

Most Recent Peer-reviewed Publications

  1. Double-blinded, randomized phase II study using embolization with or without granulocyte-macrophage colony-stimulating factor in uveal melanoma with hepatic metastases
  2. Biology of advanced uveal melanoma and next steps for clinical therapeutics
  3. Expression of insulin-like growth factor-1 receptor in metastatic uveal melanoma and implications for potential autocrine and paracrine tumor cell growth
  4. Integrin receptors on tumor cells facilitate NK cell-mediated antibody-dependent cytotoxicity
  5. Tumor necrosis factor-α blockade and development of uveal melanoma: Expected adverse effect or just coincidence?
  6. Early arterial stasis during resin-based yttrium-90 radioembolization: Incidence and preliminary outcomes
  7. Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: A randomized clinical trial
  8. High-dose vincristine sulfate liposome injection (Marqibo) is not associated with clinically meaningful hematologic toxicity
  9. The potential role of sunitinib targeting melanomas
  10. Somatostatin receptor scintigraphy in patients with metastatic uveal melanoma
  11. A pilot study of sunitinib malate in patients with metastatic uveal melanoma
  12. Uveal melanoma trapped in the temple of doom
  13. Interleukin 6 mediates production of interleukin 10 in metastatic melanoma
  14. Lymph node ratio is an important and independent prognostic factor for patients with stage III melanoma
  15. Interleukin 10 in the tumor microenvironment: A target for anticancer immunotherapy
  16. Toxicities after radioembolization with yttrium-90 SIR-spheres: Incidence and contributing risk factors at a single center
  17. Moxifloxacin prophylaxis for chemoembolization or embolization in patients with previous biliary interventions: A pilot study
  18. Side-branch embolization before 90Y radioembolization: Rate of recanalization and new collateral development
  19. Tumor-derived interleukin-10 as a prognostic factor in stage III patients undergoing adjuvant treatment with an autologous melanoma cell vaccine
  20. Summary and assessment